<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8" /><title>IMMZ.D5.DT.Rabiescontraindications</title><link rel="stylesheet" type="text/css" href="includes/dmn.css" /></head><body><table xmlns="" class="decision"><tr class="decision-header"><td class="row-label">Decision ID</td><td colspan="100"><span class="decision-id">IMMZ.D5.DT.Rabiescontraindications</span><span class="decision-name">IMMZ.D5.DT.Rabiescontraindications</span></td></tr><tr class="io-row"><td class="row-label">Inputs/Outputs</td><td class="input">Potential contraindications</td></tr><tr class="rule"><td class="row-label"></td><td class="inputEntry">
          "Potential contraindications" = "Severe allergic reactions"
          The client has history of severe allergic reactions
        </td><td class="outputEntry">
          "Immunization recommendation status" = "Further evaluation needed"
          Clinical judgement is required. Create a clinical note
        </td><td class="outputEntry">
          Check if the client has a history of severe hypersensitivity to any of the components or to excipients listed by the vaccine manufacturer. If so, provide an alternative rabies vaccine product for PreP.
          Check if the client has a history of severe hypersensitivity to any of the components or to excipients listed by the vaccine manufacturer. If so, provide an alternative rabies vaccine product for PreP.
        </td><td class="annotationEntry">
          Individuals with a history of severe hypersensitivity to any of the components or to excipients listed by the vaccine manufacturer should receive an alternative rabies vaccine product for pre-exposure prophylaxis (PreP).

In view of the almost invariably fatal outcome of rabies, there is no contraindication to PrEP vaccination.

WHO recommendations apply only to inactivated modern, concentrated, purified cell culture and embryonated egg-based rabies vaccines (CCEEVs).
        </td><td class="annotationEntry">
          Rabies vaccines: WHO position paper (April 2018) (24)
        </td><td class="annotationEntry">
          Individuals with a history of severe hypersensitivity to any of the components or to excipients listed by the vaccine manufacturer should receive an alternative rabies vaccine product for pre-exposure prophylaxis (PreP).

In view of the almost invariably fatal outcome of rabies, there is no contraindication to PrEP vaccination.

WHO recommendations apply only to inactivated modern, concentrated, purified cell culture and embryonated egg-based rabies vaccines (CCEEVs).
        </td><td class="annotationEntry">
          Rabies vaccines: WHO position paper (April 2018) (24)
        </td></tr></table></body></html>